Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2022 16:30 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00...
September 13, 2022 17:30 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer

NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancerNGM120 has been well tolerated to date in patients in the Phase 1b combination...
September 06, 2022 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress

NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancerNGM120 has been well tolerated to date in patients in the Phase 1a study with...
August 15, 2022 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial of NGM120 in Patients with Advanced Pancreatic Cancer at the American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer

Poster presentation at upcoming ESMO Annual Congress to highlight analysis of subgroup of patients with prostate cancer in NGM120 Phase 1a trialShort-talk presentation at upcoming AACR Special...
August 04, 2022 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results

--Initiated Phase 1/1b clinical trial of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with...
June 30, 2022 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer

-- William J. Rieflin to transition from Executive Chairman to Chairman of the Board of Directors -- SOUTH SAN FRANCISCO, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc....
June 23, 2022 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022

--NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy, will be showcased in the fourth of a four-part...
June 02, 2022 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
May 24, 2022 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022

--NGM707, NGM Bio’s most advanced myeloid reprogramming antibody product candidate, will be showcased in the third of a four-part series titled the “Explorer Series”-- SOUTH SAN FRANCISCO, Calif.,...
May 12, 2022 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

--Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA®-- --All three of...